Regulatory updates & industry news
Tracking enforcement actions, reclassification developments, and market shifts in the peptide space.
A Peptide Seller Went to Prison for Forging Lab Reports
Paradigm Peptides' owner was sentenced to 70 months on July 30, 2026 for selling unapproved drugs backed by forged certificates of analysis. Six products sold as SARMs contained actual testosterone. The first major criminal sentencing in the research-use-only peptide market.
6 min readTwo of These Registered "Peptide Trials" Say They Are Fictional
Eight ClinicalTrials.gov records for BPC-157, GHK-Cu, TB-500, MOTS-c and more share one sponsor, one hospital, and one contact address. Two describe themselves as fictional or mock studies in their own submitted text. Why an NCT number is not a credential.
8 min readCorrection: The "First BPC-157 RCT" Is Not a Real Trial
We covered a registered BPC-157 trial in March 2026. It turns out to belong to a batch of eight registrations from one sponsor at one site — two of which state in their own submitted text that they are fictional or mock records. Our correction, and how to read a trial registry.
7 min readFDA Proposes to Permanently Exclude Compounded Semaglutide, Tirzepatide, and Liraglutide
FDA's May 1, 2026 proposal would strike the three leading GLP-1s from the 503B outsourcing-facility bulks list on a 'no clinical need' finding — a permanent step beyond the shortage-list dynamics. The public comment period was extended to July 30, 2026.
8 min readNew Study Finds No Definitive Signal of Harm From First-Trimester GLP-1 Exposure
A June 2026 Annals of Internal Medicine study of 3,572 pregnancies found similar outcomes whether women continued or stopped a GLP-1 at conception — measured reassurance for accidental exposure, though label guidance to discontinue in pregnancy still stands.
7 min readRetatrutide's Pivotal Obesity Trial Reports at ADA 2026 — and a New Safety Signal
TRIUMPH-1, retatrutide's largest trial, showed 28.3% average weight loss at 80 weeks and improved sleep apnea and knee pain — but also surfaced a urinary tract infection signal, mostly in women, that had not appeared in earlier trials.
7 min readDoes This Mean BPC-157 Is Legal Now?
FDA review does not mean approval, 503A is not over-the-counter access, and compounding is not FDA approval. A precise answer to the BPC-157 legal-status confusion.
6 min readThe July 2026 PCAC Peptide Vote: Results for All Seven Substances
FDA's Pharmacy Compounding Advisory Committee recommended six of seven peptides for the 503A bulks list on July 24, 2026 — overruling FDA's own reviewers, who opposed all seven. Vote tallies, evidence grades, and why none of them is legal to compound yet.
7 min readFDA Calls July PCAC Meeting on Seven Peptide Bulk Drug Substances
On April 16, 2026, the FDA published a Federal Register notice (FR 2026-07361) convening the Pharmacy Compounding Advisory Committee for July 23-24 to consider seven peptide bulk drug substances — including BPC-157 — for the 503A Bulks List, and opening docket FDA-2025-N-6895.
6 min readRetatrutide Clears First Late-Stage Diabetes Trial: TRANSCEND-T2D-1 Results
Eli Lilly's triple agonist retatrutide showed A1C reductions of up to 2.0% and weight loss of up to 16.8% in the TRANSCEND-T2D-1 Phase 3 trial — with dysesthesia rates dramatically lower than TRIUMPH-4.
7 min readSemaglutide Compounding Under Scrutiny: The Novo Nordisk Supply Update
As GLP-1 supply normalizes and lawsuits mount, compounded semaglutide faces an uncertain future. What consumers need to know.
7 min readFDA Enforcement and the Gray Market: What's Happening in 2026
From criminal prosecutions and prison sentences to manufacturer lawsuits and import alerts, the pressure on unregistered peptide sellers keeps widening. A timeline of enforcement actions and what they signal.
8 min readWhat Happened to Peptide Sciences
The largest gray-market peptide vendor shut down on March 6, 2026. Here's what happened, why it matters, and what comes next.
6 min readWhat Are Compounding Pharmacies and Why Do They Matter for Peptides?
Compounding pharmacies are central to legal peptide access. Here's how they work, the 503A vs 503B distinction, and what reclassification means for the industry.
8 min readKennedy Peptide Reclassification: What Changed and What It Means
Correction: we could not verify the reported February 2026 HHS peptide reclassification against any primary source, and have removed the claim. What the public record actually shows about peptide compounding policy — and why the July 2026 advisory committee vote is the real development.
7 min readUnderstanding Peptide Categories: FDA's Classification System Explained
The FDA's Category 1, 2, and 3 system determines which peptides can be compounded. Here's how it works, what's in each category, and why reclassification matters.
7 min read